HIV co-receptor drugs on the horizon.
Bob
B
Huff
D000634:Aminoquinolines; D001562:Benzimidazoles; D002082:Butylamines; D065100:CCR5 Receptor Antagonists; D004345:Drug Industry; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006573:Heterocyclic Compounds, 1-Ring / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*
D000634:Aminoquinolines; D001562:Benzimidazoles; D002082:Butylamines; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D006573:Heterocyclic Compounds, 1-Ring; D019718:Receptors, CXCR4; C494414:mavorixafor